Renaissance Technologies (RenTech)'s KLRS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 149,351 shares of Kalaris Therapeutics, Inc. (KLRS) worth $607,859, representing 0.00% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 6 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in KLRS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 83,200 shares. Largest reduction occurred in Q4 2025, reducing 25,000 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Kalaris Therapeutics (KLRS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Kalaris Therapeutics (KLRS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +83,200 | Add 125.77% | 149,351 | $4.07 |
| Q1 2026 | -21,600 | Reduce 24.62% | 66,151 | $5.77 |
| Q4 2025 | -25,000 | Reduce 22.17% | 87,751 | $8.44 |
| Q3 2025 | +16,000 | Add 16.54% | 112,751 | $5.78 |
| Q2 2025 | +77,500 | Add 402.58% | 96,751 | $2.67 |
| Q1 2025 | +19,251 | New Buy | 19,251 | $8.03 |
Renaissance Technologies (RenTech)'s Kalaris Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Kalaris Therapeutics, Inc. (KLRS) in Q1 2025, acquiring 19,251 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Kalaris Therapeutics, Inc. (KLRS) for 6 quarters since Q1 2025.
Renaissance Technologies (RenTech)'s largest addition to Kalaris Therapeutics, Inc. (KLRS) was in Q2 2026, adding 149,351 shares worth $607,859.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 149,351 shares of Kalaris Therapeutics, Inc. (KLRS), valued at approximately $607,859.
As of the Q2 2026 filing, Kalaris Therapeutics, Inc. (KLRS) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Kalaris Therapeutics, Inc. (KLRS) was 149,351 shares, as reported at the end of Q2 2026.